GB0201179D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB0201179D0
GB0201179D0 GBGB0201179.9A GB0201179A GB0201179D0 GB 0201179 D0 GB0201179 D0 GB 0201179D0 GB 0201179 A GB0201179 A GB 0201179A GB 0201179 D0 GB0201179 D0 GB 0201179D0
Authority
GB
United Kingdom
Prior art keywords
sup
therapeutic agents
hcv
hepatitis
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0201179.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to GBGB0201179.9A priority Critical patent/GB0201179D0/en
Publication of GB0201179D0 publication Critical patent/GB0201179D0/en
Priority to US10/500,971 priority patent/US20050130997A1/en
Priority to DE60325692T priority patent/DE60325692D1/de
Priority to EP03700366A priority patent/EP1470113B1/en
Priority to CA002473508A priority patent/CA2473508A1/en
Priority to AT03700366T priority patent/ATE420078T1/de
Priority to PCT/GB2003/000124 priority patent/WO2003062211A1/en
Priority to JP2003562091A priority patent/JP4498745B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
GBGB0201179.9A 2002-01-18 2002-01-18 Therapeutic agents Ceased GB0201179D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0201179.9A GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents
US10/500,971 US20050130997A1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors
DE60325692T DE60325692D1 (de) 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren
EP03700366A EP1470113B1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors
CA002473508A CA2473508A1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors
AT03700366T ATE420078T1 (de) 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren
PCT/GB2003/000124 WO2003062211A1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors
JP2003562091A JP4498745B2 (ja) 2002-01-18 2003-01-15 ピリミジノンウイルスポリメラーゼ阻害剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201179.9A GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB0201179D0 true GB0201179D0 (en) 2002-03-06

Family

ID=9929352

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0201179.9A Ceased GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents

Country Status (8)

Country Link
US (1) US20050130997A1 (https=)
EP (1) EP1470113B1 (https=)
JP (1) JP4498745B2 (https=)
AT (1) ATE420078T1 (https=)
CA (1) CA2473508A1 (https=)
DE (1) DE60325692D1 (https=)
GB (1) GB0201179D0 (https=)
WO (1) WO2003062211A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
HRP20130971T1 (hr) 2004-02-20 2013-11-08 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
NZ565269A (en) 2005-08-01 2010-03-26 Merck & Co Inc Macrocyclic peptides as HCV NS3 protease inhibitors
CA2622639C (en) * 2005-10-04 2012-01-03 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
AU2007309488B2 (en) 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CA2667146C (en) 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
BRPI0718161A2 (pt) 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CA2672250C (en) 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2010533699A (ja) 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎感染症の治療のための大環状インドール誘導体
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
US8242140B2 (en) * 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
EA019327B1 (ru) 2008-07-22 2014-02-28 Мерк Шарп Энд Домэ Корп. Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
MX2011008276A (es) 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CA2755023C (en) * 2009-03-25 2016-12-13 Abbott Laboratories Antiviral compounds and uses thereof
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2013001273A (es) * 2010-08-13 2013-04-10 Hoffmann La Roche Compuestos heterociclicos antivirales.
WO2012151567A1 (en) * 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DE19817265A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
BR9913406A (pt) * 1998-09-04 2002-01-29 Viropharma Inc Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase

Also Published As

Publication number Publication date
DE60325692D1 (de) 2009-02-26
EP1470113A1 (en) 2004-10-27
US20050130997A1 (en) 2005-06-16
ATE420078T1 (de) 2009-01-15
EP1470113B1 (en) 2009-01-07
JP4498745B2 (ja) 2010-07-07
JP2005524627A (ja) 2005-08-18
WO2003062211A1 (en) 2003-07-31
CA2473508A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
GB0201179D0 (en) Therapeutic agents
GB0017676D0 (en) Inhibitors of viral polymerase
NZ526703A (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
NZ514403A (en) Fused-ring compounds and use thereof as drugs
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
GEP20094751B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
GEP20063938B (en) Hepatitis c virus inhibitors
AU2003240488A1 (en) Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
WO2005054430A3 (en) Hepatitis c virus inhibitors
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
JO2403B1 (en) Nickeloside derivatives antiviral
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
CA2480583A1 (en) Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)